Achyut Healthcar

Why is Achyut Healthcare Ltd falling/rising?

As of 24-Jun, Achyut Healthcare Ltd's stock price is falling by 8.32% after a strong performance, despite a 146.18% increase over the past year. The recent decline follows a new 52-week high and underperformance against its sector, indicating a potential correction phase.

As of 24-Jun, Achyut Healthcare Ltd's stock price is currently falling, with a change of -0.76, representing an 8.32% decrease. This decline comes after a period of strong performance, as the stock had previously experienced seven consecutive days of gains. Despite this recent drop, the stock has shown impressive returns over various periods, including a 146.18% increase over the past year and a 52.18% rise year-to-date.<BR><BR>Today, the stock hit a new 52-week high of Rs.10.04, indicating strong upward momentum prior to the current decline. However, it has underperformed its sector by 10.28% today, which may contribute to the downward pressure on the stock price. Additionally, while the stock is trading above its moving averages, the recent trend reversal after a series of gains suggests a correction phase.<BR><BR>Investor participation has increased, with a delivery volume rise of 29.75% against the 5-day average, indicating ongoing interest in the stock. Nevertheless, the combination of today's underperformance relative to the sector and the natural tendency for stocks to correct after a significant rally may explain the current decline in Achyut Healthcare Ltd's stock price.

Which are the latest news on Achyut Healthcar?

Should I buy, sell or hold Achyut Healthcare Ltd?

What does Achyut Healthcar do?

Achyut Healthcare Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of 4 Cr and a net profit of 0 Cr for the quarter ending March 2026, with a market cap of INR 157 Cr. The company has a P/E ratio of 537.00 and a return on equity of 0.91%.

Overview:<BR>Achyut Healthcare Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>Achyut Healthcare Limited was incorporated in 1996 as Achyut Securities Private Limited and later changed its name to Achyut Healthcare Private Limited in 2002. The most recent quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 4 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 0 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 157 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 537.00<BR>- Industry P/E: 21<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.09<BR>- Return on Equity: 0.91%<BR>- Price to Book: 4.55<BR><BR>Contact Details:<BR>Registrar Address: Not available.

How big is Achyut Healthcar?

As of 10th June, Achyut Healthcare Ltd has a market capitalization of 157.00 Cr, with recent net sales of 9.43 Cr and a net profit of 0.30 Cr over the last four quarters. Shareholder's funds are valued at 31.30 Cr, and total assets amount to 32.58 Cr as of March 2025.

As of 10th June, <BR><BR>Market Cap: Achyut Healthcare Ltd has a market capitalization of 157.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 9.43 Cr, while the sum of Net Profit for the same period is 0.30 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds are valued at 31.30 Cr, and Total Assets amount to 32.58 Cr.

Who are in the management team of Achyut Healthcar?

The management team of Achyut Healthcar includes Jigen Jagdishbhai Modi (Managing Director & CFO), Mahendra C Raycha (Chairman), Akshit Raycha (Non-Executive Director), Amisha Jigen Modi (Executive Director), and independent directors Rutvik Sanjaykumar Thakkar and Sonu Lalitkumar Jain.

The management team of Achyut Healthcar includes the following individuals:<BR><BR>1. **Jigen Jagdishbhai Modi** - Managing Director & CFO<BR>2. **Mahendra C Raycha** - Chairman & Non-Executive Director<BR>3. **Akshit Raycha** - Non-Executive Director<BR>4. **Amisha Jigen Modi** - Executive Director<BR>5. **Rutvik Sanjaykumar Thakkar** - Independent Non-Executive Director<BR>6. **Sonu Lalitkumar Jain** - Independent Non-Executive Director<BR><BR>If you have any more questions about the company or its management, feel free to ask!

Who are the peers of the Achyut Healthcar?

Achyut Healthcar's peers include Auro Labs, Kimia Bioscien, Natural Capsules, Panch. Organics, Parnax Lab, Krebs Biochem, Alpa Laboratorie, Quest Laborato, and Accretion Pha. Achyut Healthcar has the highest 1-year return at 70.39%, while its management risk and growth are rated as below average compared to some peers.

Peers: The peers of Achyut Healthcar are Auro Labs., Kimia Bioscien., Natural Capsules, Panch.Organics, Parnax Lab, Krebs Biochem, Alpa Laboratorie, Quest Laborato., and Accretion Pha.<BR><BR>Quality Snapshot: Excellent management risk is observed at Accretion Pha., while Average management risk is found at Auro Labs., Panch.Organics, Alpa Laboratorie, and the rest. Below Average management risk is noted at Kimia Bioscien., Natural Capsules, Achyut Healthcar, Parnax Lab, and Krebs Biochem. For Growth, Excellent growth is seen at Accretion Pha. and Parnax Lab, while Average growth is noted at Achyut Healthcar, and Below Average growth is present at Auro Labs., Kimia Bioscien., Natural Capsules, Panch.Organics, and the rest. In terms of Capital Structure, Excellent capital structure is found at Panch.Organics, Parnax Lab, and Alpa Laboratorie, while Good capital structure is observed at Achyut Healthcar and Accretion Pha., and Below Average capital structure is noted at Auro Labs., Kimia Bioscien., Natural Capsules, and the rest.<BR><BR>Return Snapshot: Achyut Healthcar has the highest 1-year return at 70.39%, while Natural Capsules has the lowest at -35.45%. Compared to its peers, Achyut Healthcar's return is significantly higher. Additionally, the six-month returns are negative for Auro Labs., Natural Capsules, Panch.Organics, Alpa Laboratorie, and Krebs Biochem.

Are Achyut Healthcare Ltd latest results good or bad?

Achyut Healthcare Ltd's latest results show significant growth in net sales and profit, but concerns about thin profit margins, revenue volatility, and high valuation suggest an unfavorable outlook. Investors should be cautious, as risks may outweigh the positives.

Achyut Healthcare Ltd's latest results present a mixed picture. On one hand, the company reported a significant quarter-on-quarter increase in both net sales and net profit for Q4 FY26, with net sales rising by 179.62% to ₹4.39 crores and net profit increasing by 500% to ₹0.06 crores. This dramatic growth might seem promising at first glance.<BR><BR>However, a deeper analysis reveals serious concerns. The company's profit margins are extremely thin, with a PAT margin of just 1.37% and an operating profit margin of only 0.68%. Such low margins indicate that the core pharmaceutical operations are not generating meaningful profitability. Additionally, the company's return on equity (ROE) stands at a mere 1.74%, which is among the lowest in the sector, highlighting weak capital efficiency.<BR><BR>The volatility in revenue is alarming, with sales fluctuating significantly from quarter to quarter, suggesting instability in the business model. For instance, the previous quarter (Q3 FY26) saw a decline in sales by 38.43% from Q2 FY26. This inconsistency raises questions about the company's operational stability.<BR><BR>Furthermore, the valuation metrics are concerning. Achyut Healthcare trades at a P/E ratio of 250.57, which is extraordinarily high compared to industry peers, indicating that the market may be overvaluing the stock relative to its financial performance.<BR><BR>In summary, while the latest results show some positive growth figures, the underlying profitability issues, revenue volatility, and extreme valuation suggest that the overall outlook for Achyut Healthcare is not favorable. Investors should approach with caution, as the risks appear to outweigh the positives.

When is the next results date for Achyut Healthcare Ltd?

The next results date for Achyut Healthcare Ltd is 27 May 2026.

The next results date for Achyut Healthcare Ltd is scheduled for 27 May 2026.

How has been the historical performance of Achyut Healthcar?

Achyut Healthcar's historical performance shows fluctuating financial metrics, with net sales peaking at 6.14 Cr in March 2024 before declining to 3.05 Cr in March 2025. The company maintained a zero-debt status while experiencing operating losses and an increase in total liabilities and assets during this period.

Answer:<BR>The historical performance of Achyut Healthcar shows a fluctuating trend in its financial metrics over the years.<BR><BR>Breakdown:<BR>Achyut Healthcar's net sales have varied significantly, with a peak of 6.14 Cr in March 2024, followed by a decline to 3.05 Cr in March 2025. The total operating income mirrored this trend, reaching 6.14 Cr in March 2024 and dropping to 3.05 Cr in March 2025. The company experienced operating losses, with an operating profit (PBDIT) of 0.72 Cr in March 2025, slightly down from 0.76 Cr in March 2024. Profit before tax also showed a slight decrease from 0.74 Cr in March 2024 to 0.70 Cr in March 2025, while profit after tax increased from 0.50 Cr to 0.55 Cr during the same period. The total liabilities rose from 30.95 Cr in March 2024 to 32.58 Cr in March 2025, reflecting an increase in trade payables and current liabilities. Total assets also increased from 30.95 Cr to 32.58 Cr, primarily driven by growth in current assets, which amounted to 12.06 Cr in March 2025, down from 21.47 Cr in March 2024. The company maintained a zero-debt status throughout the years, indicating no long-term or short-term borrowings.

Who are the top shareholders of the Achyut Healthcar?

The top shareholders of Achyut Healthcar include Mahendra C Raycha Huf as the largest promoter with 10.21%, and Dharm Prakash Tripathi as the highest public shareholder at 16.26%. Individual investors hold 39.82% of shares, while foreign institutional investors account for 8.14%, with no pledged promoter holdings or mutual funds involved.

The top shareholders of Achyut Healthcar include a mix of promoters and public investors. The majority shareholders are the promoters, with Mahendra C Raycha Huf being the promoter with the highest holding at 10.21%. The highest public shareholder is Dharm Prakash Tripathi, who holds 16.26%. Additionally, individual investors collectively hold 39.82% of the shares, while foreign institutional investors (FIIs) hold 8.14% through three different entities. There are no pledged promoter holdings, and no mutual funds are involved in the company's shareholding.

Is Achyut Healthcar overvalued or undervalued?

As of May 30, 2025, Achyut Healthcar is considered a risky investment due to its overvaluation indicated by a PE ratio of 82.45, negative operational efficiency ratios, and poor returns on capital and equity, despite a recent positive stock return.

As of 30 May 2025, Achyut Healthcar's valuation grade has moved from does not qualify to risky, indicating a significant shift in its perceived financial health. The company is currently deemed overvalued, particularly highlighted by its PE ratio of 82.45, which is substantially higher than peers like MMTC Ltd. at 119.39 and Optiemus Infracom Ltd. at 82.35. Additionally, Achyut's EV to EBIT and EV to EBITDA ratios are both at -82.07, suggesting severe operational inefficiencies.<BR><BR>The company's ROCE stands at -0.72% and ROE at 1.79%, further underscoring its struggles in generating returns for shareholders. Compared to its peers, Achyut Healthcar's valuation metrics are concerning, especially when juxtaposed with PTC India Ltd., which has a PE ratio of just 9.02 and is classified as very attractive. Despite a recent positive stock return of 5.11% over the past week compared to the Sensex's 1.37%, the overall trend indicates that Achyut Healthcar remains a risky investment, with its long-term performance trailing behind the broader market.

What is the technical trend for Achyut Healthcar?

As of April 23, 2025, Achyut Healthcar's trend is mildly bearish, with mixed signals from indicators like the MACD, Bollinger Bands, and moving averages, suggesting some positive momentum but overall weakness.

As of 23 April 2025, the technical trend for Achyut Healthcar has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, suggesting some positive momentum, while the monthly MACD is mildly bearish, indicating a potential longer-term weakness. The Bollinger Bands are signaling a mildly bearish stance on both weekly and monthly time frames. Daily moving averages also reflect a mildly bearish trend. The Dow Theory shows no trend on the weekly chart but is mildly bullish on the monthly, which adds some complexity to the overall view. The RSI shows no signals on both time frames, indicating a lack of momentum. Overall, the current stance is mildly bearish with mixed signals across different indicators.

What is the bonus history of the Achyut Healthcar?

Achyut Healthcare's recent bonus history includes a 4:10 ratio announced on December 10, 2024, and a 1:2 ratio issued on April 25, 2023.

Achyut Healthcare has a notable bonus history. The most recent bonus issue was a 4:10 ratio announced for December 10, 2024. Prior to that, on April 25, 2023, the company issued a bonus in a 1:2 ratio. If you have any more questions about the company or its financial activities, feel free to ask!

Has Achyut Healthcar declared dividend?

No Dividend History Available